**SPECIAL FEATURES**

**CCR Translations**

- **1189** PET Imaging of Tumor Growth: Not as Easy as It Looks
  - Anthony E. Shields
  - See article p. 1303

- **1192** Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety
  - David L. Bajor and Robert H. Vonderheide
  - See article p. 1386

**CCR New Strategies**

- **1195** New Strategies in Melanoma: Molecular Testing in Advanced Disease
  - Scott E. Woodman, Alexander J. Lazar, Kenneth D. Aldape, and Michael A. Davies

**Molecular Pathways**

- **1201** Molecular Pathways: Beta-Adrenergic Signaling in Cancer
  - Steven W. Cole and Anil K. Sood

- **1207** Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
  - Asis Palazón, Julián Aragonés, Aízea Morales-Kastresana, Manuel Ortiz de Landázuri, and Ignacio Melero

**Review**

- **1214** Here, There Be Dragons: Charting Autophagy-Related Alterations in Human Tumors
  - Chandra B. Lebovitz, Svetlana B. Bortnik, and Sharon M. Gorski

**HUMAN CANCER BIOLOGY**

- **1227** Activation of PI3K Signaling in Merkel Cell Carcinoma
  - Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barría, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Byan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, and Dora Dias-Santagata

**CANCER THERAPY: PRECLINICAL**

- **1268** Telomestatin Impairs Gliona Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb
  - Takeshi Miyazaki, Yang Pan, Kaushal Joshi, Deepri Purohit, Bin Hu, Habibe Denir, Sarmittha Mazumder, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, and Ichiro Nakano
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, and Richard A. Scolyer

See commentary p. 1192

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Andres Forero-Torres, Sven de Vos, Brad L. Pohlman, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, and Kristen N. Ganjoo

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

David S. Yoo, John P. Kirkpatrick, Oma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Duphney, Neal E. Ready, and David M. Brizel

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors


CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma

Kesuke Aoe, Vishwa Jeet Amatyas, Nobuaki Fujimoto, Kei Ohnuma, Osamu Hosono, Akio Hiraki, Masanori Fujii, Taketo Yamada, Nam H. Dang, Yukio Takeshima, Kouki Inai, Takumi Kishimoto, and Chikao Morimoto

Sunitinib Therapy for Melanoma Patients with KIT Mutations

David R. Minor, Mohammed Kashani-Sabet, Maria Garrido, Steven J. O’Day, Omid Hamid, and Boris C. Bastian

Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer

Julie K. Schwarz, Jacqueline E. Payton, Ramachandran Rashmi, Tao Xiang, Yunhe Jia, Phyllis Huettner, Buck E. Rogers, Qin Yang, Mark Watson, Janet S. Rader, and Perry W. Grigsby

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew J. Weickhardt, Kimi L. Kondok, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marie J. Varella-Garcia, and D. Ross Camidge

Correction: Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Correction: Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
ABOUT THE COVER

Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.